Skip to main content
Thorax logoLink to Thorax
. 2006 Mar 3;61(6):503–506. doi: 10.1136/thx.2005.044909

Risk factors for the development of bronchiolitis obliterans in children with bronchiolitis

A J Colom 1,2,3, A M Teper 1,2,3, W M Vollmer 1,2,3, G B Diette 1,2,3
PMCID: PMC2111218  PMID: 16517579

Abstract

Background

Bronchiolitis obliterans (BO) is an uncommon and severe form of chronic obstructive lung disease in children that results from an insult to the lower respiratory tract.

Methods

A case‐control study of children under the age of 3 years was performed in 109 cases and 99 controls to determine risk factors for the development of BO. Participants were evaluated by immunofluorescence viral tests, pulmonary function tests, and questions to assess tobacco and other exposures.

Results

Bronchiolitis due to adenovirus (odds ratio (OR) 49, 95% confidence interval (CI) 12 to 199) and the need for mechanical ventilation (OR 11, 95% CI 2.6 to 45) were strongly and independently associated with an increased risk for BO. Factors not associated with post‐infectious BO included age of the child, sex, and environmental tobacco exposure (either in utero or during infancy).

Conclusions

Adenovirus infection and need for mechanical ventilation are significant risk factors for developing BO in children. Further research is needed to determine why these risk factors are so strong and how they may contribute to the development of the disease.

Keywords: adenovirus infections, lung function tests, respiratory insufficiency, bronchiolitis obliterans, mechanical ventilation, infants


Bronchiolitis obliterans (BO) is an uncommon and severe form of chronic obstructive lung disease in children that results from an insult to the lower respiratory tract, which occurs in a number of forms. Included in the clinical scenarios reported in the literature are after Stevens‐Johnson syndrome, as a complication of graft versus host disease in bone marrow transplant recipients, and as a manifestation of chronic graft rejection in lung transplant recipients. However, in many parts of the world BO is most commonly seen in children after severe viral lower respiratory tract infections.1 Clinically, it is characterised by tachypnoea, increased anteroposterior chest diameter, crackles, wheezing, and hypoxaemia for at least 30 days after the initial injury.2 Pathologically, BO is characterised by luminal obstruction with inflammation, granulation tissue, and/or fibrosis and obliteration of the small airways and bronchiectasis.3

Post‐infectious BO has been reported mainly in the southern hemisphere (Argentina, Chile, southern Brazil, Australia, and New Zealand) where its impact can be profound. In the respiratory centre at Ricardo Gutiérrez Children's Hospital in Buenos Aires, for example, post‐infectious BO accounted for 14% of all bed‐days during the 10 year period from 1993 to 2002.

A number of respiratory viruses—including respiratory syncytial virus (RSV),4 parainfluenza,5 influenza,6 and especially adenovirus (AV)7—were associated with severe lung injury leading to BO. Although BO has been observed commonly after viral infections, research has not yet quantified the importance of specific viruses as risk factors for BO. Our current knowledge of post‐infectious BO is based largely on a few case series in which the antecedent risk factors have not been clearly identified.8,9,10

To address this knowledge gap, we performed a case‐control study of children in Buenos Aires, Argentina to determine risk factors for the development of post‐infectious BO.

Methods

Potential cases included all children treated for post‐infectious BO from 1991 to 2002 at the Children's Hospital in Buenos Aires, Argentina (identified from retrospective chart review). The children were aged 3 years or younger with chronic respiratory insufficiency (defined as tachypnoea, increased anteroposterior chest diameter, crackles, wheezing, and hypoxaemia (Sao2 <93%) lasting for at least 30 days after the initial injury) following severe bronchiolitis in a previously healthy infant.2 Children with co‐existing cystic fibrosis, congenital heart disease, or primary ciliary dyskinesia were excluded. One hundred and nine children met these criteria.

Control subjects were identified from the population of new cases of bronchiolitis (first episode of wheeze) who were admitted to our hospital during 2002 and who did not subsequently develop BO. A 12 month period was chosen to encompass the full spectrum of bronchiolitis cases seen during a year and thus to avoid biases associated with seasonality. Similar exclusion criteria were applied to controls as to cases. A total of 161 potential controls were identified in this manner, 99 of whom met the inclusion/exclusion criteria.

Indirect inmunofluorescence viral testing of nasopharyngeal secretions was performed to identify AV, RSV, influenza, and parainfluenza virus. These tests are routinely done on patients admitted for bronchiolitis so were available in the medical records of most cases (64%) and controls (93%). Several patients with post‐infectious BO were initially treated in other hospitals and viral test results were not available for them.

Chest radiographs and HRCT scans were reviewed and interpreted by two experienced paediatric radiologists. Pulmonary function tests (PFTs) were routinely performed only in patients with BO. They were carried out when the patient's condition was stable (absence of an acute respiratory tract infection for 30 days, lack of upper airway secretions, and normal haemodynamic parameters). Partial forced flow/volume curves and compliance and resistance measurements were done according to the ATS/ERS guidelines.11 Values of maximal flow at functional residual capacity (V′maxFRC) were expressed as Z scores.12,13

Data on current exposure to environmental tobacco smoke (ETS) and exposure to ETS during pregnancy were obtained from the medical records or from interviews with the parents.

Statistical analysis

Assuming that 10% of the control subjects would have had exposure to AV, the study had 80% power to detect a 16% difference in AV exposure probabilities between cases and controls. Risk factors were assessed using logistic regression analysis and the results are reported as odds ratios (OR) with 95% confidence intervals (CI). Interaction terms were used to test for lack of additivity of effects on the ln(odds) scale. The following variables were considered as potential risk factors for post‐infectious BO: sex, prenatal and postnatal ETS exposure, age <6 months at time of admission for bronchiolitis, evidence of specific viral aetiologies for the bronchiolitis, and the need for mechanical ventilation during the target admission. The 6 month age cut off was used because 67% of the patients were younger than 6 months.

Analyses were performed using Stata for Windows (Stata Corp, College Station, TX, USA) and Epi‐Info (US Department of Health and Human Services/Centers for Disease Control and Prevention, Atlanta, USA) statistical software packages. A p value of ⩽0.05 indicated statistical significance.

Results

Participants ranged in age from 1 to 26 months at the time of their initial admission for bronchiolitis, with a mean age of 7 months among cases and 5 months among controls (table 1); 60% of cases and 58% of controls were boys. The number of new cases of post‐infectious BO during the period of the study showed substantial variation from year to year (fig 1). Almost all (98%) of the controls were admitted in the fall or winter compared with 75% of patients with post‐infectious BO. In those post‐infectious BO patients tested, AV was detected in 72%, RSV in 10%, parainfluenza in 4%, and influenza in 1%. In control patients, RSV was the virus most frequently identified (58%), and only 3% were positive for AV. 34% of patients with post‐infectious BO required mechanical ventilation compared with only 3% of patients in the control group. The median stay in hospital was 30 days (range 11–120) in post‐infectious BO patients and 6 days (range 1–40) in controls.

Table 1 Study population and risk factors for developing post‐infectious BO (bivariate analysis).

Progressed to BO OR 95% CI p value
Yes (n = 109) No (n = 99)
Median (range) age (months) 6 (1–26) 5 (1–20)
 <6 months 67% 72% 0.5 0.3 to 0.9 0.02
Male 60% 58% 1.1 0.6 to 2 0.8
Admitted in fall or winter 75% 98% 1.0 0.8 to 1.2 0.9
ETS exposure in uterus 24% 12% 1.6 0.7 to 4 0.3
Current ETS exposure 59% 38% 2.2 1.2 to 4 0.01
Adenovirus infection 72% 3% 83 22 to 441 <0.001
Mechanical ventilation 34% 3% 12 5 to 34 <0.001

ETS, environmental tobacco smoke.

graphic file with name tx44909.f1.jpg

Figure 1 Cases of post‐infectious BO by calendar year.

In bivariate analyses AV infection (OR 83, 95% CI 22 to 441) and the need for mechanical ventilation (OR 12, 95% CI 5 to 34) were exceptionally strong risk factors (table 1), and persisted as significant predictors of risk for post‐infectious BO in multivariate logistic regression models (table 2). A formal test for interaction in the logistic model was not significant.

Table 2 Multivariate logistic regression analysis of risk factors for BO.

Variable OR 95% CI p value
Age (<6 v ⩾6 months) 1.4 0.4 to 5.4 0.6
Sex (male v female) 0.8 0.2 to 2.6 0.7
ETS at present 1.4 0.4 to 4.5 0.5
ETS during pregnancy 0.4 0.1 to 3.2 0.4
Adenovirus infection 49 12 to 199 <0.001
Mechanical ventilation 11 2.6 to 45 0.001

ETS, environmental tobacco smoke.

Clinical findings

Chest radiography and PFTs were performed at the time of the clinical evaluation of the post‐infectious BO cases, which occurred a mean of 4 months after the onset of illness (range 5–30). Patients with BO had high respiratory rates (mean 37 breaths/min, range 35–40); 70% (56/80) had a rigid thorax, 74% (69/93) had wheeze, and 89% (81/91) had persistent productive cough. Oxygen saturation was lower than normal (mean (SD) Sao2 92 (5)%). Most children were not malnourished (mean (SD) Z score length for age −1.6 (1), weight for length −0.45 (1)).

Chest radiographs from 98 of the patients with post‐infectious BO showed air trapping (96%), atelectasis (75%), areas with an increased interstitial pattern (55%), and honeycombing (34%). The most frequent findings on the HRCT scans (reported for 62 of the cases) were mosaic perfusion (60%), bronchiectasis (58%), and atelectasis (44%).

Pulmonary function tests were performed in 75 of the 109 patients with post‐infectious BO (68%) and showed severe fixed airflow obstruction (mean (SD) V′maxFRC Z score −3.1 (0.8); fig 2), decreased compliance (1.21 (0.5) ml/cm H2O/kg), and increased resistance (0.05 (0.02) cm H2O/ml/seg). The mean bronchodilator response was 7%. Some patients did not perform the test because they were more than 2 years old or because of the severity of the illness.

graphic file with name tx44909.f2.jpg

Figure 2 Pulmonary function of patients with post‐infectious BO.

Most of the patients with post‐infectious BO (57%) required oxygen supplementation after discharge from the initial hospital admission for a median period of 17 months (range 1–62), and the majority (95%) required readmission to hospital for subsequent infections of the lower respiratory tract. Hypoxaemia improved slowly over several years and only 3% (1/37) remained on supplemental oxygen at the age of 6 years.

Discussion

This study includes the largest sample of paediatric patients with post‐infectious BO in the medical literature to date. The results show that AV infection and the need for mechanical ventilation are strong independent risk factors for developing post‐infectious BO in children under 3 years of age. During the last two decades there have been a growing number of reports of patients with post‐infectious BO. Although there are no worldwide studies of the prevalence of post‐infectious BO, it has mainly been reported in certain areas including Argentina, Brazil, Chile, New Zealand, Canada, and South Korea. For unknown reasons, large areas such as the US and Europe have had only a small number of reports.2,8,9,10 Reasons for the difference in the prevalence of the disease may include the severity of the AV infections according to the serotype and to a genetic predisposition to develop the disease, particularly among unique populations derived from populations native to those regions.14,15,16,17

The central role of AV in the development of post‐infectious BO has been well documented.14 In our study AV was identified in 71% of the patients with post‐infectious BO in whom diagnostic testing was performed. Although since 1984 a new genotype of adenovirus, AV7h, has stood out as the most virulent serotype, other AVs (such as 3, 5, and 21) also cause BO.15 Epidemiological studies indicate that the global prevalence patterns of AV genome types do shift over time and geographical region, which may make it technically difficult to develop a new vaccine with broad applicability.18

Patients with severe AV infection have been shown to have immune complexes containing AV antigen in the lung, as well as increased serum levels of interleukin‐6, interleukin‐8, and tumour necrosis factor‐α.19,20 These previous studies suggest that a specific immunological response may be important in the development of BO following AV infection.21 In the present study, illness occurred in very young infants—67% were younger than 6 months and 93% were younger than 12 months—but our findings did not show that age was a risk factor for developing post‐infectious BO. In previous studies patients admitted with bronchiolitis and malnutrition had a more severe course;22 however, malnutrition was not an important factor in the present study as most of the children were not malnourished.

Although AV was identified in most of the post‐infectious BO patients at the onset of the illness, other viruses were also found. RSV is the most frequent casual agent of bronchiolitis and occurs mainly during winter months. An association between BO and RSV has been reported only rarely,4,23 and the pathogenesis of BO is not clear in these patients. Simultaneous infections of RSV and AV have also been reported.23,24 In these cases it would seem most likely that the AV infection is the cause of BO. About one quarter of the total diagnosed cases infected with influenza develop complications, mostly in younger children (0–4 years of age).25 However, BO is a rare complication of influenza with only a few cases reported in infancy and early childhood.6

The use of mechanical ventilation, an important treatment for children in intensive care units, has apparently allowed severely ill children to survive who previously would have died before BO could be recognised. Mechanical ventilation is indispensable for the support of critically ill patients with respiratory insufficiency. Although our study found that mechanical ventilation was a significant risk factor for post‐infectious BO, our results do not indicate whether it causes injury to the lung that increases the risk for developing post‐infectious BO or whether it merely serves as an indicator of severity of illness. Mechanisms by which mechanical ventilation could cause lung injury include untoward effects from volutrauma, oxygen toxic effects, and barotrauma.26 Further research is needed to clarify the relationship between mechanical ventilation and post‐infectious BO, and to study whether lung protective strategies are needed for this vulnerable population. Cidofovir, a new antiviral agent is under investigation and may be an alternative for the treatment of AV infection in the future.27

The ethnic background of patients is another factor that has been linked with the risk for developing post‐infectious BO. Two ethnic indigenous populations of children in New Zealand and central Canada16,17 have been reported to be particularly susceptible to developing post‐infectious BO, which suggests that genetic factors may be important.28 Our study evaluated children of different geographical origins but did not assess ethnicity. The relationship of post‐infectious BO to race/ethnicity is an interesting and important topic for future research.

All tested patients with post‐infectious BO had a V′maxFRC that was more severely affected than in other diseases such as bronchopulmonary dysplasia or asthma which, even in their most severe forms, usually respond to bronchodilators. This finding confirms our previous report about the use of PFTs which enable us to improve the diagnostic approach to post‐infectious BO.2 We believe that the patient's clinical history and the radiological and HRCT images are sufficient in most cases to confirm the diagnosis and to differentiate post‐infectious BO from other pulmonary disorders.2 These clinical evaluations should be considered in tandem with the functional pattern which, in post‐infectious BO, is characterised by severe and fixed obstruction, an increase in resistance, and a decrease in lung compliance. In the few cases in which doubt persists about the diagnosis, a lung biopsy may be needed.

We conclude that both AV infection and mechanical ventilation are strongly associated with the development of post‐infectious BO. The immunological response of the host and genetically determined factors could be additional factors that modify or increase susceptibility to the condition. Strategies to prevent infection with AV, such as development of a vaccine, should be encouraged to prevent this devastating illness. In the meantime, early recognition is vital so that children can be isolated to prevent the spread of infection to others. When AV is suspected or isolated, early aggressive treatment is warranted, and future clinical studies are required to determine the best treatment strategies.

Acknowledgements

The authors thank Dr Sonia Buist and the staff of the ATS International Respiratory Epidemiology Course for encouraging our research and helping to improve the paper, and Dr Carlos Kofman for performing most of the infant pulmonary function tests.

Abbreviations

AV - adenovirus

BO - bronchiolitis obliterans

ETS - environmental tobacco smoke

PFT - pulmonary function test

RSV - respiratory syncytial virus

V′maxFRC - maximal flow at functional residual capacity

Footnotes

Funding: Methods in Epidemiologic, Clinical and Operations Research (MECOR program), American Thoracic Society.

Competing interests: none.

References

  • 1.Hardy K A, Schidlow D V, Zaeri N. Obliterative bronchiolitis in children. Chest 198893460–466. [DOI] [PubMed] [Google Scholar]
  • 2.Teper A M, Kofman C D, Maffey A F.et al Lung function in infants with chronic pulmonary disease after severe adenoviral illness. J Pediatr 1999134730–733. [DOI] [PubMed] [Google Scholar]
  • 3.Becroft D M O. Bronchiolitis obliterans, bronchiectasis, and other sequelae of adenovirus type 21 infection in young children. J Clin Pathol 19712472–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Krasinski K. Severe respiratory syncytial virus infection: clinical features, nosocomial acquisition and outcome. Pediatr Infect Dis J 19854250–257. [DOI] [PubMed] [Google Scholar]
  • 5.Welliver R, Wong D, Sun M.et al Parainfluenza virus bronchiolitis. Am J Dis Child 198614034–40. [DOI] [PubMed] [Google Scholar]
  • 6.Laraya‐Cuasay L R, DeForest A, Huff D.et al Chronic pulmonary complications of early influenza virus infection in children. Am Rev Respir Dis 1977116617–625. [DOI] [PubMed] [Google Scholar]
  • 7.Simila S, Linna O, Lanning P.et al Chronic lung damage caused by adenovirus type 7: a ten year follow up study. Chest 198180127–131. [DOI] [PubMed] [Google Scholar]
  • 8.Chang A, Masel J, Masters B. Post‐infectious bronchiolitis obliterans: clinical, radiological and pulmonary function sequelae. Pediatr Radiol 19982823–29. [DOI] [PubMed] [Google Scholar]
  • 9.Zhang L, Irion K, Kozakewich H.et al Clinical course of postinfectious bronchiolitis obliterans. Pediatr Pulmonol 200029341–350. [DOI] [PubMed] [Google Scholar]
  • 10.Kim C K, Kim S W, Kim J S.et al Bronchiolitis obliterans in the 1990s in Korea and the United States. Chest 20011201101–1106. [DOI] [PubMed] [Google Scholar]
  • 11.Hoo A F, Dezateux C, Hanrahan J P.et al Sex‐specific prediction equations for Vmax(FRC) in infancy: a multicenter collaborative study. Am J Respir Crit Care Med 20021651084–1092. [DOI] [PubMed] [Google Scholar]
  • 12.Hanrahan J P, Tager I B, Castile R G.et al Pulmonary function measures in healthy infants. Variability and size correction. Am Rev Respir Dis 19901411127–1135. [DOI] [PubMed] [Google Scholar]
  • 13.Hiatt P, Eigen H, Yu P.et al Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis 1988137119–122. [DOI] [PubMed] [Google Scholar]
  • 14.Sly P D, Soto‐Quiros M E, Landau L I.et al Factors predisposing to abnormal pulmonary function after adenovirus type 7 pneumonia. Arch Dis Child 198459935–939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kajon A, Mistchenko A, Videla C.et al Molecular epidemiology of adenoviruses associated with acute lower respiratory infections of children in the south cone of South America (1991–1994). J Med Virol 199648151–156. [DOI] [PubMed] [Google Scholar]
  • 16.Lang W, Howden C, Laws J.et al Bronchopneumonia with serious sequelae in children with evidence of adenovirus type 21 infection. BMJ 1969173–79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Wenman W, Pagtakhan R, Reed M.et al Adenovirus bronchiolitis in Manitoba. Epidemiologic, clinical and radiologic features. Chest 198281605–609. [DOI] [PubMed] [Google Scholar]
  • 18.Purkayastha A, Su J, McGraw J.et al Genomic and bioinformatics analyses of HAdV‐4vac and HAdV‐7vac, two human adenovirus (HAdV) strains that constituted original prophylaxis against HAdV‐related acute respiratory disease, a reemerging epidemic disease. J Clin Microbiol 2005433083–3094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mistchenko A S, Lenzi H L, Thompson F M.et al Participation of immune complexes in adenovirus infection. Acta Paediatr 199281983–988. [DOI] [PubMed] [Google Scholar]
  • 20.Mistchenko A S, Diez R A, Mariani A L.et al Cytokines in adenoviral disease in children: association of interleukin‐6, interleukin‐8, and tumor necrosis factor alpha levels with clinical outcome. J Pediatr 1994124714–720. [DOI] [PubMed] [Google Scholar]
  • 21.Mistchenko A S, Koch E R R, Kajon A E.et al Lymphocyte subsets and cytokines in adenoviral infection in children. Acta Paediatr 199887933–939. [DOI] [PubMed] [Google Scholar]
  • 22.Law B J, Carbonell‐Estrany X, Simoes E A. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med 200296(Suppl B)S1–S7. [PubMed] [Google Scholar]
  • 23.Massie R, Armstrong D. Bronchiectasis and bronchiolitis obliterans post respiratory syncytial virus infection: think again. J Paediatr Child Health 199935497–498. [DOI] [PubMed] [Google Scholar]
  • 24.Hirschheimer M, Silva P, Giudici R.et al Simultaneous viral infection and childhood bronchiolitis obliterans. Braz J Infect Dis 20026146–148. [DOI] [PubMed] [Google Scholar]
  • 25.Loughlin J, Poulios N, Napalkov P.et al A study of influenza and influenza‐related complications among children in a large US health insurance plan database. Pharmacoeconomics 200321273–283. [DOI] [PubMed] [Google Scholar]
  • 26.Pinhu L, Whitehead T, Evans T.et al Ventilator‐associated lung injury. Lancet 2003361332–340. [DOI] [PubMed] [Google Scholar]
  • 27.De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 200316569–596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Wohl M E, Chernick V. State of the art: bronchiolitis. Am Rev Respir Dis 1978118759–781. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES